Lv11
50 积分 2024-05-09 加入
Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
2小时前
已关闭
Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
3天前
已完结
Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
3天前
已完结
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
3天前
已完结
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
3天前
已完结
NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
4天前
已关闭
A Phase 1 First‐in‐Human Pharmacokinetic and Pharmacodynamic Study of JNJ‐64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase
6天前
已完结
Validation for soluble C5b-9 detection and comparative analysis of three quantification methods
10天前
已完结
Challenges for complement functional assays in the clinical laboratory: From test validation to clinical interpretation
10天前
已完结
Bioanalytical approaches to support the development of antibody-oligonucleotide conjugate (AOC) therapeutic proteins
11天前
已完结
皖公网安备34019202002308
